• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cure Pharmaceutical touts data from Curefilm Blue trial for erectile dysfunction

April 21, 2021 By Sean Whooley

Cure PharmaceuticalCure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform.

Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, but said the results are positive and will help it move forward development of the Curefilm Blue platform.

Curefilm Blue is based on Cure’s proprietary Curefilm fast-dissolving drug delivery platform. It delivers the active pharmaceutical ingredient sildenafil citrate to move drug delivery beyond traditional pills and solutions while also aiming to enhance the patient experience.

“These results further validate CURE’s oral soluble film dosage form, establishing our drug delivery technology platform, and offering patients a better experience and an opportunity to avoid the need to swallow a pill,” Cure CSO Dr. Vered Gigi said in the release.

“As the first of many of CURE’s specialty pharmaceutical programs, we are excited by this outcome. We are now accelerating our partnering initiatives with an eye toward future commercialization,” added chief business officer Jonathan Berlent.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Cure Pharmaceutical

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS